Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix, Inc. (NASDAQ:SNGX) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 46,600 shares, a drop of 32.6% from the March 15th total of 69,100 shares. Based on an average trading volume of 214,200 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.5% of the shares of the stock are sold short.

Soligenix Trading Up 1.9 %

Shares of Soligenix stock opened at $2.10 on Friday. The stock has a market capitalization of $5.27 million, a price-to-earnings ratio of -0.28 and a beta of 1.85. The firm’s 50-day moving average price is $2.22 and its two-hundred day moving average price is $2.85. Soligenix has a 1-year low of $1.68 and a 1-year high of $14.83.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. During the same period in the prior year, the business earned ($12.66) earnings per share. As a group, equities research analysts predict that Soligenix will post -4.65 EPS for the current year.

Institutional Investors Weigh In On Soligenix

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC lifted its position in shares of Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,094 shares of the biopharmaceutical company’s stock after acquiring an additional 7,729 shares during the quarter. Geode Capital Management LLC owned approximately 1.04% of Soligenix worth $71,000 at the end of the most recent reporting period. 3.60% of the stock is owned by institutional investors and hedge funds.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.